Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hearing implant trial aims to help kids hear better

NCT ID NCT06976086

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests the Sentio bone-anchored hearing system in 50 children aged 3 to 11 with hearing loss or single-sided deafness. The device is already approved for older kids and adults. Researchers want to see if it safely improves hearing compared to no aid. The trial is happening at eight European hospitals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sentio bone-anchored hearing system (implant and sound processor)
What this could lead to
If successful, this could expand access to a proven hearing solution for younger children, improving their hearing and quality of life.
What could go wrong
This is a small, early-stage study with only 50 children, so results may not apply to all. There are surgical risks and possible device-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 11 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed Informed Consent Form (depending on age of child, signed by parent or legal guardian and child) 2. Subject aged 3 to 11 years 3. Subject with: 3.1 conductive or mixed hearing losses with pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear better than or equal to 45 dB HL. 3.2 OR subject who has a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. SSD). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz) 3.3 OR subject indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS. 4. Subject and parent or legal guardian have the ability and willingness to comply with investigational procedures/ requirements, as determined by the investigator. 5. Subject with prior experience of amplified sound through a properly fitted hearing aid, a CROS device, or a non-surgical bone anchored solution (e.g. softband). 6. For subject with conductive or mixed hearing losses, ensure sufficient air bone gap (ABG) at the ear to be implanted. 7. Sufficient bone quality/quantity/depth or skull size for implantation of a Sentio Ti implant as assessed according to clinical practice. Exclusion Criteria: 1. Medical condition that contraindicates implant surgery or anesthesia as judged by the investigator. 2. Untreated ongoing middle ear infection at the time of surgery. 3. Known or suspected contact allergy to silicone or other material used in the Sentio system. 4. Known condition that could jeopardize wound healing and skin condition, e.g. uncontrolled diabetes over time, as judged by the investigator. 5. Known skin or scalp conditions that may preclude attachment or interfere with the usage of the sound processor. 6. Evidence of conditions that would prevent good speech recognition potential as determined by good clinical judgment. 7. Any other known condition that the investigator determines could interfere with compliance or investigation assessments. 8. Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator. 9. Subject that has received radiotherapy in the area of implantation or is planned for such radiotherapy or similar during the investigation period. 10. For bilateral asymmetric candidates, subject already treated with a bone-anchored hearing solution on the side with the best bone conduction thresholds. 11. Known chronic or non-revisable vestibular or balance disorder. 12. Known abnormally progressive hearing loss. 13. Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Sentio system as determined by the investigator. 14. Use of active implantable or body worn device that for medical reasons cannot be removed or discontinued, such as CSF shunts, implantable cardiac pacemakers, defibrillators, or neurostimulators. 15. Known need for frequent MRI investigations for follow-up of other diseases. 16. Any subject that according to the Declaration of Helsinki is deemed unsuitable for investigation enrolment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hearing loss, conductive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Birmingham Children's hospital, Birmingham Women's and Children's NHS Foundation Trust

    Birmingham, B4 6NH, United Kingdom

  • Great Ormond Street Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust

    London, WC1N 3JH, United Kingdom

  • Hospital Universitario Virgen Macarena

    Seville, 41009, Spain

  • Hospital Universitario de Donostia

    San Sebastián, 20014, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, 46026, Spain

  • Radboud University Medical Center

    Nijmegen, 6525EX, Netherlands

  • The Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust

    London, SE1 7EH, United Kingdom

  • University Medical Center Groningen

    Groningen, 9700 RB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.